Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Alcon Inc. Ordinary Shares (NY:ALC)

79.18 -1.86 (-2.30%)
Official Closing Price Updated: 4:10 PM EDT, Aug 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Alcon Inc. Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9 Next >
These Analysts Slash Their Forecasts On Alcon After Q2 Earnings
 
Via Benzinga
Palantir, AI Stocks Extend Losses Ahead Fed Minutes: What's Moving Markets Wednesday?
A second day of selling pressure hit technology stocks tied to the AI theme on Wednesday, as sentiment cooled after an MIT report questioned the broad profitability of the new technology. 
Via Benzinga
Topics Artificial Intelligence Economy
Alcon Cites Tariffs And Soft Market In Lowered Sales Outlook, Shares Fall
Alcon cut its 2025 outlook citing higher tariffs, with Q2 sales missing estimates. Earnings topped forecasts, led by strong vision care demand. 
Via Benzinga
Topics World Trade
La-Z-Boy Posts Downbeat Q1 Results, Joins James Hardie Industries, Alcon And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
 
Via Benzinga
What Analysts Are Saying About Alcon Stock
 
Via Benzinga
An Overview of Alcon's Earnings
 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
Why Rocket Pharmaceuticals Shares Are Trading Higher By Over 15%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
 
Via Benzinga
Alcon Earnings Preview
 
Via Benzinga
These stocks are moving in today's after hours session
Discover the top movers in Tuesday's after-hours session and stay informed about the post-market dynamics. 
Via Chartmill
Alcon Reports Second-Quarter 2025 Results, Launched Tryptyr and Announced Acquisition of STAAR Surgical
From Alcon Inc. Investors
Via Business Wire
Tech Stocks Drop, Palantir Plunges Over 8%: What's Moving Markets Tuesday?
Tech stocks pulled back on Tuesday as the absence of fresh bullish catalysts prompted investors to take profits after the recent months-long rally. 
Via Benzinga
Earnings Scheduled For August 19, 2025
 
Via Benzinga
Predicting the Next Rule Breaker Buyout
Having a stock you own get acquired at a premium feels good at first, but what about the long-term gains that will be left behind when your chips are off the table? 
Via The Motley Fool
Topics Artificial Intelligence
10 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: WideOpenWest, Inc. (NYSE - WOW), BankFinancial Corporation (Nasdaq - BFIN), STAAR Surgical Company (Nasdaq – STAA), Y-mAbs Therapeutics, Inc. (Nasdaq – YMAB)
From Brodsky & Smith LLC
Via GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: STAAR Surgical Company (Nasdaq – STAA), Y-mAbs Therapeutics, Inc. (Nasdaq – YMAB), Couchbase, Inc. (Nasdaq – BASE), Core Scientific, Inc. (Nasdaq - CORZ)
From Brodsky & Smith LLC
Via GlobeNewswire
Alcon Expands Vision Correction Portfolio With STAAR Surgical Acquisition
Alcon will acquire STAAR Surgical for $1.5 billion to expand surgical vision correction options for high myopia, including EVO ICL lenses. 
Via Benzinga
Alcon Agrees to Acquire STAAR Surgical
From Alcon Inc. Investors
Via Business Wire
Alcon to Acquire LumiThera and Its Photobiomodulation Device for the Treatment of Early and Intermediate Dry Age-Related Macular Degeneration (AMD)
From Alcon Inc. Investors
Via Business Wire
Artificial Intelligence Influence in Ophthalmology Industry Projected to Create a Billion Dollar Revenue Opportunity
EQNX::TICKER_START (OTCQB:AVAI),(NYSE:ALC),(NYSE:BLCO),(NYSE:JNJ),(NASDAQ:TEM) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Artificial Intelligence
Alcon Secures First FDA Approval Since Novartis Spin-Off In 2019
FDA approves Alcon's Tryptyr for dry eye disease, backed by Phase 3 trials showing strong efficacy in increasing natural tear production. 
Via Benzinga
Alcon Announces FDA Approval of TRYPTYR (acoltremon ophthalmic solution) 0.003% for the Treatment of the Signs and Symptoms of Dry Eye Disease
From Alcon Inc. Investors
Via Business Wire
Alcon, American Eagle, GRAIL And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
 
Via Benzinga
American Eagle, Cisco Systems And 3 Stocks To Watch Heading Into Wednesday
 
Via Benzinga
Alcon Reports First-Quarter 2025 Results and Launches Transformational Change in Ophthalmic Surgery with Unity VCS
From Alcon Inc. Investors
Via Business Wire
Alcon Announces Results of 2025 Annual General Meeting
From Alcon Inc. Investors
Via Business Wire
Earnings Scheduled For May 13, 2025
 
Via Benzinga
Alcon Elevates Vitreoretinal and Cataract Surgery for Superior Efficiency* with UNITY VCS and UNITY CS
From Alcon Inc. Investors
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.